Trader consensus on Polymarket reflects an 84.5% implied probability for no new WHO-designated COVID variant of concern (VOC) before 2027, driven by the lack of escalation for recent subvariants despite heightened surveillance. The highly mutated BA.3.2 "Cicada" lineage, detected in over 30 U.S. states and 33 countries since late March 2026, has surged to prominence with faster spread and some immune escape potential, particularly in children, but shows no evidence of increased severity or hospitalization rates. Classified only as a Variant Under Monitoring (VUM) by ECDC and WHO as of mid-April, it aligns with patterns of ongoing SARS-CoV-2 evolution tempered by broad population immunity from vaccines and prior infections. Traders anticipate continued monitoring without VOC criteria—transmissibility, virulence, or therapeutic escape—being met amid falling case severity trends.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$235,425 Vol.
$235,425 Vol.
$235,425 Vol.
$235,425 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Market Opened: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Trader consensus on Polymarket reflects an 84.5% implied probability for no new WHO-designated COVID variant of concern (VOC) before 2027, driven by the lack of escalation for recent subvariants despite heightened surveillance. The highly mutated BA.3.2 "Cicada" lineage, detected in over 30 U.S. states and 33 countries since late March 2026, has surged to prominence with faster spread and some immune escape potential, particularly in children, but shows no evidence of increased severity or hospitalization rates. Classified only as a Variant Under Monitoring (VUM) by ECDC and WHO as of mid-April, it aligns with patterns of ongoing SARS-CoV-2 evolution tempered by broad population immunity from vaccines and prior infections. Traders anticipate continued monitoring without VOC criteria—transmissibility, virulence, or therapeutic escape—being met amid falling case severity trends.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions